
    
      This is a prospective, multicenter, single arm, phase II trial in elderly patients (â‰¥ 70
      years) affected by DLBCL defined as frail according to CGA and previously untreated.

      The primary endpoint is to evaluate the efficacy of the R2 (Revlimid+Rituximab) combination
      in first line DLBCL patients not candidate for the standard R-CHOP (or R-CHOP like)
      treatments due to the frail status.
    
  